IDH1 and astrocytoma (excluding glioblastoma): A recent, multicenter study suggested that non-IDH1-R132H IDH1/2 mutations are associated with an improved survival for astrocytomas compared to their R132H-mutant counterpart [19], which provides a basis for analyzing these rare mutations.